Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients
ObjectiveTo estimate the cost-effectiveness of adding serplulimab to chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC) patients in a first-line setting from a Chinese perspective.MethodsA three-health state partitioned survival model was constructed to simulate disease developm...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1382088/full |
| _version_ | 1797198712980635648 |
|---|---|
| author | Hanrui Zheng Hanrui Zheng Ya Zeng Feng Wen Feng Wen Ming Hu |
| author_facet | Hanrui Zheng Hanrui Zheng Ya Zeng Feng Wen Feng Wen Ming Hu |
| author_sort | Hanrui Zheng |
| collection | DOAJ |
| description | ObjectiveTo estimate the cost-effectiveness of adding serplulimab to chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC) patients in a first-line setting from a Chinese perspective.MethodsA three-health state partitioned survival model was constructed to simulate disease development. The clinical data used in the model were derived from the ASTRUM-004 clinical trial. Only direct medical costs were included, and the utilities were derived from published literature. The quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER) were employed to evaluate health outcomes. Additionally, a sensitivity analysis was performed to verify the robustness of the results.ResultsCompared with chemotherapy alone, the addition of serplulimab resulted in an increase of 0.63 QALYs with an incremental cost of $5,372.73, leading to an ICER of $8,528.14 per QALY. This ICER was significantly lower than 3 times China’s per capita GDP. The one-way sensitivity analysis suggested that the utility of PFS was the most sensitive factor on ICERs, followed by the price of serplulimab.ConclusionThe combination of serplulimab and chemotherapy has been shown to be a cost-effective initial treatment option for patients with metastatic squamous NSCLC with the commonly accepted willingness-to-pay threshold of 3 times the GDP per capita per QALY in China. |
| first_indexed | 2024-04-24T07:04:14Z |
| format | Article |
| id | doaj.art-596d8ccde70e42a88ee2120d0346e815 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T07:04:14Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-596d8ccde70e42a88ee2120d0346e8152024-04-22T04:48:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-04-011510.3389/fimmu.2024.13820881382088Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patientsHanrui Zheng0Hanrui Zheng1Ya Zeng2Feng Wen3Feng Wen4Ming Hu5West China School of Pharmacy, Sichuan University, Chengdu, ChinaDepartment of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaWest China Biomedical Big Data Center, Sichuan University, Chengdu, ChinaWest China School of Pharmacy, Sichuan University, Chengdu, ChinaObjectiveTo estimate the cost-effectiveness of adding serplulimab to chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC) patients in a first-line setting from a Chinese perspective.MethodsA three-health state partitioned survival model was constructed to simulate disease development. The clinical data used in the model were derived from the ASTRUM-004 clinical trial. Only direct medical costs were included, and the utilities were derived from published literature. The quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER) were employed to evaluate health outcomes. Additionally, a sensitivity analysis was performed to verify the robustness of the results.ResultsCompared with chemotherapy alone, the addition of serplulimab resulted in an increase of 0.63 QALYs with an incremental cost of $5,372.73, leading to an ICER of $8,528.14 per QALY. This ICER was significantly lower than 3 times China’s per capita GDP. The one-way sensitivity analysis suggested that the utility of PFS was the most sensitive factor on ICERs, followed by the price of serplulimab.ConclusionThe combination of serplulimab and chemotherapy has been shown to be a cost-effective initial treatment option for patients with metastatic squamous NSCLC with the commonly accepted willingness-to-pay threshold of 3 times the GDP per capita per QALY in China.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1382088/fullcost-effectivenessserplulimabchemotherapysquamous non-small cell lung cancerpartitioned survival model |
| spellingShingle | Hanrui Zheng Hanrui Zheng Ya Zeng Feng Wen Feng Wen Ming Hu Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients Frontiers in Immunology cost-effectiveness serplulimab chemotherapy squamous non-small cell lung cancer partitioned survival model |
| title | Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients |
| title_full | Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients |
| title_fullStr | Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients |
| title_full_unstemmed | Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients |
| title_short | Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients |
| title_sort | cost effectiveness of additional serplulimab to chemotherapy in metastatic squamous non small cell lung cancer patients |
| topic | cost-effectiveness serplulimab chemotherapy squamous non-small cell lung cancer partitioned survival model |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1382088/full |
| work_keys_str_mv | AT hanruizheng costeffectivenessofadditionalserplulimabtochemotherapyinmetastaticsquamousnonsmallcelllungcancerpatients AT hanruizheng costeffectivenessofadditionalserplulimabtochemotherapyinmetastaticsquamousnonsmallcelllungcancerpatients AT yazeng costeffectivenessofadditionalserplulimabtochemotherapyinmetastaticsquamousnonsmallcelllungcancerpatients AT fengwen costeffectivenessofadditionalserplulimabtochemotherapyinmetastaticsquamousnonsmallcelllungcancerpatients AT fengwen costeffectivenessofadditionalserplulimabtochemotherapyinmetastaticsquamousnonsmallcelllungcancerpatients AT minghu costeffectivenessofadditionalserplulimabtochemotherapyinmetastaticsquamousnonsmallcelllungcancerpatients |